ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery

被引:47
作者
Baiocchi, Glauco [1 ,2 ]
Lopes, Ademar [3 ]
Coudry, Renata A. [4 ]
Rossi, Benedito M. [3 ]
Soares, Fernando A. [4 ]
Aguiar, Samuel [3 ]
Guimaraes, Gustavo C. [3 ]
Ferreira, Fabio O. [3 ]
Nakagawa, Wilson T. [3 ]
机构
[1] Hosp Canc AC Camargo, Dept Ginecol, BR-01509010 Sao Paulo, Brazil
[2] Hosp Canc AC Camargo, Dept Gynecol Oncol, BR-01509010 Sao Paulo, Brazil
[3] Hosp Canc AC Camargo, Dept Pelv Surg, BR-01509010 Sao Paulo, Brazil
[4] Hosp Canc AC Camargo, Dept Pathol, BR-01509010 Sao Paulo, Brazil
关键词
Colonic neoplasm; Rectal neoplasm; Prognosis; ErbB; Microarray analysis; Immunohistochemistry; GROWTH-FACTOR RECEPTOR; AMERICAN JOINT COMMITTEE; HUMAN-BREAST-CANCER; PROGNOSTIC-SIGNIFICANCE; COLON-CANCER; TISSUE MICROARRAYS; PROTEIN EXPRESSION; CURATIVE SURGERY; EGFR EXPRESSION; RECTAL-CANCER;
D O I
10.1007/s00384-009-0702-6
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Investigate ErbB family expression in colorectal cancer patients with higher risk of recurrence after surgical treatment. We studied 109 individuals with high risk stage II and stage III patients submitted to radical surgery. ErbB expression was assessed by tissue microarray technique. The immunohistochemical expression was considered positive for EGFR, ErbB2, ErbB3, ErbB4 membrane, and ErbB4 cytoplasmic in respectively 57.8%, 8.3%, 69.7%, 11%, and 19.3% of patients. ErbB3 negative expression was associated with lymphovascular invasion. EGFR, ErbB2, and cytoplasmic ErbB4 expression was not associated with prognosis. Membranous positive ErbB4 expression was an independent prognostic factor for recurrence. ErbB3 negative expression was an independent prognostic factor for recurrence and survival in the multivariate analysis. The immunohistochemical expression of ErbB3 and ErbB4 may identify a subgroup with stage II and III colorectal cancer at higher risk of recurrence.
引用
收藏
页码:1059 / 1068
页数:10
相关论文
共 49 条
  • [1] [Anonymous], Global Cancer Facts Figures, V3rd
  • [2] American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer
    Benson, AB
    Schrag, D
    Somerfield, MR
    Cohen, AM
    Figueredo, AT
    Flynn, PJ
    Krzyzanowska, MK
    Maroun, J
    McAllister, P
    Van Cutsem, E
    Brouwers, M
    Charette, M
    Haller, DG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) : 3408 - 3419
  • [3] EGF-ERBB signalling: towards the systems level
    Citri, Ami
    Yarden, Yosef
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2006, 7 (07) : 505 - 516
  • [4] Compton C, 2000, CANCER-AM CANCER SOC, V88, P1739, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1739::AID-CNCR30>3.0.CO
  • [5] 2-T
  • [6] Compton CC, 2000, ARCH PATHOL LAB MED, V124, P979
  • [7] Cunningham MP, 2006, INT J ONCOL, V28, P329
  • [8] Essapen S, 2004, INT J ONCOL, V24, P241
  • [9] ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation
    Feroz, K
    Williams, E
    Riese, DJ
    [J]. CELLULAR SIGNALLING, 2002, 14 (09) : 793 - 798
  • [10] Finnegan Timothy J, 2007, Future Oncol, V3, P55, DOI 10.2217/14796694.3.1.55